Abecma Or Bust: 2seventy Sells Final Research Program To Novo

 
• By Jessica Merrill

2seventy bio sold full rights to a hemophilia A program and in vivo gene editing technology to partner Novo Nordisk.

hemophilia
2Seventy sold rights to a hemophilia A program to Novo Nordisk • Source: Shutterstock

More from Deals

More from Business